undamentalytics Newsletter
Sign in

Clearpoint Neuro, Inc. (CLPT) stock

Add to watchlist

Add holding +

NASDAQ: CLPT Nasdaq Health Care Equipment Next results ~January 15, 2027

C Fundamentals grade

Clearpoint Neuro, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Clearpoint Neuro, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Clearpoint Neuro, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 4 selling0 purchases and 9 sales by directors and officers, last 12 monthsInsider trades
  • Funds67 adding, 41 cuttingOf 13 active managers that changed their stake, 9 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Clearpoint Neuro files

Where Clearpoint Neuro stands after its latest 10-Q

Revenue for the twelve months to September 2026 was $45m, up 32.5% on a year earlier, faster than the 25.9% growth a quarter earlier. That growth ranks 18 of 103 among the health care equipment companies we cover. Free-cash-flow margin fell to -105.9% from -40.3% a year earlier. Operating margin narrowed to -70.6% from -66.3%. The diluted share count is up 6.7% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 1 of our 7 financial-health checks.

Our model value for Clearpoint Neuro is under review, so past values are not shown until it is resolved.

Source: 10-Q filed October 28, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 15, 2027 (estimated)

Clearpoint Neuro, Inc.'s trailing-twelve-month revenue grew 32.5% year on year, with a free-cash-flow margin of -105.9%. Where it stands out: change in growth rate of +6.7pp ranks 20 of 129 health care equipment companies we cover. Where it lags: long-term debt as % of assets of 45.1% ranks 72 of 87 health care equipment companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 248.5% while net income fell 56.2%: a 192pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 32.5% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Growth speeding up. The growth rate is 6.7 points higher than a quarter earlier.

Things to watch

  • Loss-making. Operating margin is -70.6%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 4.3 points on a year ago.
  • Burning cash. Free cash flow was -105.9% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 18.4% of revenue, against a median of 6.1% for health care equipment companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 6.7% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 87% and a beta of 1.7 against the S&P 500.

Latest results: FY2026 Q3

Filed October 28, 2026
Earnings per share
-$0.24 against an average estimate of -$0.32: beat by 23.8%
Revenue
$12m, up 36.3% on a year earlier
Share reaction
+10.3% in the first session after the results on October 28, 2026, against 0.0% for the S&P 500
Guidance given
revenue $48m to $50m (2026)
Next report
October 28, 2026; average EPS estimate -$0.23

Clearpoint Neuro's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-6.7%
  • 1 week+10.1%
  • 1 month-8.7%
  • This year-27.3%
  • 1 year-57.1%
  • 5 years-44.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$45.5M
Operating margin
-70.6%
Net margin
-79.4%
EPS (TTM, diluted)
$-1.21

Growth

Revenue growth
+32.5%
Change in growth rate
+6.7 pts
Share count change
+6.7%

Cash

Free cash flow (TTM)
-$48.2M
FCF margin
-105.9%
Stock pay % of revenue
18.4%

Earnings

Last results
October 28, 2026
Next results (est.)
January 15, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Clearpoint Neuro, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Clearpoint Neuro, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.11 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$1.4 ~$1.6–$6.6 Left out: out of range vs price (0.14x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Clearpoint Neuro, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$15.20$3.40$2.75$1.57$4.80$15.89$11.22$8.47$6.79$15.38$13.68$9.95
Market value$29m$9m$21m$17m$63m$252m$233m$205m$167m$416m$387m$297m
+ Net debt (− = net cash)$6m$4m−$2m$2m−$3m$5m−$44m−$18m−$13m−$20m$5m$6m
Enterprise value$34m$13m$19m$19m$60m$257m$189m$187m$154m$396m$392m$304m
Multiples
Price / sales 6.2x1.6x2.9x2.3x5.6x19.6x14.3x10.0x7.0x13.2x10.5x6.5x
Price / earnings ————————————
Price / free cash flow ————————————
EV / EBITDA ————————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

30 /100

Weak moat

How hard Clearpoint Neuro's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 1 / 20

    Cash operating profit has been a median 2.7% of total assets over 6 years.

  • Pricing power 18 / 20

    Gross margin has been a median 61.4%, moving by 3.6 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -72.3%; its worst year was -99.5%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 10 years, at a median -96.0% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 50.1% over five years; stock-based pay has been a median 19.0% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.17 −30% $49m +31%
Next −$1.10 +6% $56m +15%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +5.1% on 90 days ago. In the last 30 days, 0 analysts raised Clearpoint Neuro, Inc.'s forecast and 3 cut it.

Consensus EPS forecast Clearpoint Neuro, Inc., last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.11 Current fiscal year, 60 days ago: −$1.30 Current fiscal year, 30 days ago: −$1.30 Current fiscal year, 7 days ago: −$1.30 Current fiscal year, Now: −$1.17 −$1.17 Next fiscal year, 90 days ago: −$0.94 Next fiscal year, 60 days ago: −$1.20 Next fiscal year, 30 days ago: −$1.20 Next fiscal year, 7 days ago: −$1.20 Next fiscal year, Now: −$1.10 −$1.10

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.11−$0.94
60 days ago −$1.30−$1.20
30 days ago −$1.30−$1.20
7 days ago −$1.30−$1.20
Now −$1.17−$1.10

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$0.32 −$0.24 +23.8%
Jun 2026 −$0.29 −$0.38 −32.6%
Mar 2026 −$0.27 −$0.32 −17.1%
Dec 2025 −$0.20 −$0.27 −35.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 28, 2026
  • revenue 2026 $48m to $50m
    “The Company now estimates revenue in 2026 to be between $48.0 million and $50.0 million.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

2 analysts, Oct 2026
Buy2100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202622
  2. Sep 202622
  3. Aug 202633

Counts of recommendations published by analysts covering Clearpoint Neuro, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
14.9%
of tradable shares
Days to cover
6.11
at average volume
Short interest, 1 month
+7%
to October 15, 2026
Held by institutions
50%
of shares
Held by insiders
5.2%
of shares
Employees
172
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −57.1%

$23.22 on October 31, 2025 to $9.95

ThenNowEffect
Revenue (last 12 months) $34m $42m +25.9%
P/S multiple 19.2x 6.9x −64.2%
Share count 28m 29m −5.0%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +63.1%

$6.10 on November 3, 2023 to $9.95

ThenNowEffect
Revenue (last 12 months) $22m $42m +94.8%
P/S multiple 6.9x 6.9x −0.3%
Share count 25m 29m −16.0%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CLPT−29%−25%−20%+127%−11%−27%
Industry peers (median)−7%−37%−8%−20%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CLPT25%33%42%50%50%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CLPT−62%−53%−58%−33%−58%−54%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 94% from November 4, 2015 to September 21, 2018. Getting back needed a 1569% gain, reached on January 26, 2021, 858 days after the low.

Price behaviour

52-week range
$8.66 – $19.43
From 52-week high
−48.8%
vs 50-day average
−19.7%
vs 200-day average
−23.1%
Volatility (1 year)
87%
Beta vs S&P 500
1.74

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±11.2%
After a week
2 up, 9 down
typical move ±11.9%
After a month
4 up, 7 down
typical move ±15.8%
Results releasedNext dayS&P 500 next day5 days21 days
October 28, 2026 +10.3% 0.0% — —
August 3, 2026 −13.8% +3.3% −2.5% −0.3%
May 13, 2026 +1.0% +1.4% −11.4% +6.3%
March 17, 2026 −12.9% −1.1% −14.6% −4.8%
January 12, 2026 −3.0% 0.0% −6.8% −10.4%
November 6, 2025 −6.9% −1.0% −8.7% −19.4%
August 12, 2025 +12.5% +1.4% −1.3% +4.6%
May 13, 2025 −8.9% +0.8% −6.2% −11.4%
February 26, 2025 −15.0% −1.5% −15.3% −25.7%
November 7, 2024 −12.9% +1.2% −16.0% +9.6%
August 7, 2024 +35.8% +1.6% +47.4% +78.3%
May 7, 2024 +0.8% +0.1% +1.2% −3.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Clearpoint Neuro, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Clearpoint Neuro, Inc.
$20M $30M $40M $50M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $24M Revenue (TTM), FY24 Q1: $26.2M Revenue (TTM), FY24 Q2: $28.1M Revenue (TTM), FY24 Q3: $30.4M Revenue (TTM), FY24 Q4: $31.4M Revenue (TTM), FY25 Q1: $32.2M Revenue (TTM), FY25 Q2: $33.6M Revenue (TTM), FY25 Q3: $34.3M Revenue (TTM), FY25 Q4: $37M Revenue (TTM), FY26 Q1: $40.6M Revenue (TTM), FY26 Q2: $42.3M Revenue (TTM), FY26 Q3: $45.5M $45.5M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $24M
FY24 Q1 $26.2M
FY24 Q2 $28.1M
FY24 Q3 $30.4M
FY24 Q4 $31.4M
FY25 Q1 $32.2M
FY25 Q2 $33.6M
FY25 Q3 $34.3M
FY25 Q4 $37M
FY26 Q1 $40.6M
FY26 Q2 $42.3M
FY26 Q3 $45.5M
Revenue growth, TTM YoY Clearpoint Neuro, Inc.
10% 20% 30% 40% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 16.6% Revenue growth, TTM YoY, FY24 Q1: 24.9% Revenue growth, TTM YoY, FY24 Q2: 29.3% Revenue growth, TTM YoY, FY24 Q3: 36.3% Revenue growth, TTM YoY, FY24 Q4: 31.0% Revenue growth, TTM YoY, FY25 Q1: 23.2% Revenue growth, TTM YoY, FY25 Q2: 19.7% Revenue growth, TTM YoY, FY25 Q3: 12.8% Revenue growth, TTM YoY, FY25 Q4: 17.8% Revenue growth, TTM YoY, FY26 Q1: 26.0% Revenue growth, TTM YoY, FY26 Q2: 25.9% Revenue growth, TTM YoY, FY26 Q3: 32.5% 32.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 16.6%
FY24 Q1 24.9%
FY24 Q2 29.3%
FY24 Q3 36.3%
FY24 Q4 31.0%
FY25 Q1 23.2%
FY25 Q2 19.7%
FY25 Q3 12.8%
FY25 Q4 17.8%
FY26 Q1 26.0%
FY26 Q2 25.9%
FY26 Q3 32.5%
Operating margin (TTM) Clearpoint Neuro, Inc.
-100% -50% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -93.7% Operating margin (TTM), FY24 Q1: -80.1% Operating margin (TTM), FY24 Q2: -66.1% Operating margin (TTM), FY24 Q3: -61.8% Operating margin (TTM), FY24 Q4: -62.9% Operating margin (TTM), FY25 Q1: -67.3% Operating margin (TTM), FY25 Q2: -67.4% Operating margin (TTM), FY25 Q3: -66.3% Operating margin (TTM), FY25 Q4: -65.4% Operating margin (TTM), FY26 Q1: -65.2% Operating margin (TTM), FY26 Q2: -73.4% Operating margin (TTM), FY26 Q3: -70.6% -70.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -93.7%
FY24 Q1 -80.1%
FY24 Q2 -66.1%
FY24 Q3 -61.8%
FY24 Q4 -62.9%
FY25 Q1 -67.3%
FY25 Q2 -67.4%
FY25 Q3 -66.3%
FY25 Q4 -65.4%
FY26 Q1 -65.2%
FY26 Q2 -73.4%
FY26 Q3 -70.6%
FCF margin (TTM) Clearpoint Neuro, Inc.
-150% -100% -50% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -60.3% FCF margin (TTM), FY24 Q1: -47.6% FCF margin (TTM), FY24 Q2: -34.7% FCF margin (TTM), FY24 Q3: -29.3% FCF margin (TTM), FY24 Q4: -29.4% FCF margin (TTM), FY25 Q1: -36.4% FCF margin (TTM), FY25 Q2: -34.9% FCF margin (TTM), FY25 Q3: -40.3% FCF margin (TTM), FY25 Q4: -66.1% FCF margin (TTM), FY26 Q1: -65.7% FCF margin (TTM), FY26 Q2: -73.9% FCF margin (TTM), FY26 Q3: -105.9% -105.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -60.3%
FY24 Q1 -47.6%
FY24 Q2 -34.7%
FY24 Q3 -29.3%
FY24 Q4 -29.4%
FY25 Q1 -36.4%
FY25 Q2 -34.9%
FY25 Q3 -40.3%
FY25 Q4 -66.1%
FY26 Q1 -65.7%
FY26 Q2 -73.9%
FY26 Q3 -105.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 3 4 5 4 4 5 6 7 7 11 13 16 21 24 31 37 45
Gross profit — — — — — — — 4 5 7 9 11 14 14 19 23 28
EBITDA −9 −6 −3 −7 −5 −9 −7 −6 −5 −4 −6 −13 −16 −22 −19 −23 −32
Operating income −10 −6 −3 −7 −5 −9 −7 −6 −5 −5 −6 −13 −16 −22 −20 −24 −32
Net income −9 −8 −6 −7 −5 −8 −8 −7 −6 −6 −7 −14 −16 −22 −19 −26 −36
Diluted EPS −$56.00 −$0.52 −$0.15 −$0.12 −$0.08 −$4.48 −$2.93 −$0.93 −$0.56 −$0.42 −$0.43 −$0.69 −$0.68 −$0.90 −$0.70 −$0.90 −$1.21
Growth (year on year)
Revenue — +43.0% +32.5% −22.3% −8.3% +27.5% +25.1% +28.4% −0.4% +52.5% +14.4% +27.0% +26.1% +16.6% +31.0% +17.8% +32.5%
Margins
Gross margin — — — — — — — 60.7% 66.9% 64.9% 71.1% 68.2% 65.8% 56.8% 60.9% 61.4% 61.4%
EBITDA margin −346.5% −145.8% −53.6% −179.3% −137.1% −190.7% −127.5% −84.3% −69.9% −39.7% −45.9% −81.1% −78.3% −91.1% −59.7% −63.2% −69.3%
Operating margin −356.5% −155.1% −61.9% −190.2% −147.6% −195.3% −130.3% −85.9% −71.4% −41.0% −48.5% −82.1% −79.5% −93.7% −62.9% −65.4% −70.6%
Net margin −354.2% −217.7% −116.2% −180.3% −125.5% −183.9% −140.4% −97.1% −83.8% −49.4% −52.9% −88.4% −80.0% −92.2% −60.3% −69.1% −79.4%
Free-cash-flow margin −291.0% −164.1% −149.5% −199.8% −202.5% −189.7% −103.0% −81.6% −63.8% −25.5% −61.2% −78.9% −79.9% −60.3% −29.4% −66.1% −105.9%
Cash flow
Cash from operations −8 −6 −7 −8 −7 −9 −6 −6 −5 −3 −8 −13 −16 −14 −9 −24 −47
Capital spending 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1
Free cash flow −8 −6 −8 −8 −7 −9 −6 −6 −5 −3 −8 −13 −16 −14 −9 −24 −48
Stock-based pay 0 1 2 1 1 2 1 1 1 1 1 2 4 6 7 8 8
Free cash flow after stock pay −8 −7 −10 −9 −8 −10 −7 −7 −6 −4 −9 −15 −21 −21 −16 −33 −57
Balance sheet
Cash 2 0 2 4 9 5 3 9 3 6 20 54 28 23 20 46 46
Total debt 0 7 2 4 11 11 7 7 5 3 25 10 10 10 0 51 53
Net debt (negative = net cash) −2 7 0 0 2 6 4 −2 2 −3 5 −44 −18 −13 −20 5 6
Diluted shares — — 1m 1m 1m 2m 3m 8m 11m 13m 16m 21m 24m 25m 27m 28m 30m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 7 checks passed · September 30, 2026
What it owns · $113m
Short-term assets $67mLonger-term assets $46m
What it owes, and who funded it · $113m
Short-term liabilities $10mLonger-term liabilities $76mShareholders' equity $27m
  • Short-term assets cover short-term liabilities $67m of assets due within a year against $10m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $67m short-term assets against $76m of longer-dated liabilities.
  • More cash than debt $46m of cash against $51m of debt.
  • Debt below 40% of shareholders' equity Debt is 186% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 22% to 186% over five years.
  • A year's operating cash flow covers at least 20% of debt −$47m of operating cash flow against $51m of debt.
  • Operating profit covers interest at least five times over Operating income of −$32m against $5m of interest.

From Clearpoint Neuro, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+6.7%
year over year
R&D spending
36.1%
of revenue
Sales & admin spending
43.6%
of revenue
Days sales outstanding
64 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated CLPT KRMD TLSI SNWV MYO SENS Median
Revenue, last 12 months $45m $45m $45m $44m $43m $49m $99m
Revenue growth, last 12 months 32.5% 22.4% 25.2% 12.7% 6.1% 90.6% 9.2%
Revenue growth, 3-year average 26.8% 15.3% 45.1% 34.4% 35.4% 38.0% 13.5%
Revenue growth, latest quarter 36.3% 18.2% 1.7% −3.1% 21.3% 117.8% 10.2%
Gross margin 61.4% 62.4% 85.8% 76.3% 68.4% 54.9% 61.2%
Operating margin −70.6% −3.7% −67.7% 3.4% −27.1% −223.2% −8.5%
Operating margin, 3-year average −66.2% −13.3% −122.3% 7.0% −31.6% −261.7% −17.9%
Net margin −79.4% −4.0% −62.6% 34.7% −33.5% −225.3% −12.0%
Cash from operations / revenue −103.6% 3.1% −50.6% 11.9% −16.4% −197.6% −1.9%
Free-cash-flow margin −105.9% 1.6% −51.6% 9.6% −19.2% −199.5% −3.9%
Free-cash-flow margin, 3-year average −58.5% −2.7% −119.5% −0.8% −31.0% −230.3% −7.0%
Stock pay / revenue 18.4% 6.1% 23.6% 13.4% 6.4% 23.2% 6.1%
Change in share count 6.7% 2.5% 73.8% 78.4% 5.9% −2.8% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 32.5% 9.1% 23 of 129
Change in growth rate Growth +6.7pp -0.6pp 20 of 129
Gross margin Profitability 61.4% 61.9% 63 of 123
Operating margin Profitability -70.6% -8.3% 95 of 132
Net margin Profitability -79.4% -12.0% 100 of 133
Free-cash-flow margin Cash generation -105.9% -3.4% 105 of 128
Stock pay as % of revenue Cash generation 18.4% 6.1% 95 of 123
Long-term debt as % of assets Balance sheet 45.1% 24.2% 72 of 87
Change in share count Balance sheet 6.7% 3.3% 79 of 115
Days sales outstanding Balance sheet 64 days 57 days 77 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Products $23.9M ▲ 28.1%
Biologics and Drug Delivery $19M ▲ 10.0%
Neurosurgery Navigation and Therapy Disposable Products $14.8M ▲ 44.2%
Neurosurgery Navigation and Therapy $14.8M ▲ 44.2%
Services $13.1M ▲ 2.7%
Biologics and Drug Delivery Services and License Fees $11.7M 0.0%
Biologics and Drug Delivery Disposable Products $7.3M ▲ 30.9%
Capital Equipment and Software $3.1M ▼ 18.3%
Capital Equipment and Software Related Service $2.1M ▼ 8.7%
Capital Equipment and Software Systems and Software Products $1.7M ▼ 38.2%
Capital Equipment and Software Services $1.4M ▲ 33.0%

These categories overlap or exclude eliminations, so shares aren't shown.

From Clearpoint Neuro, Inc.'s 10-K filed March 17, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$248M
Institutions reporting
127
Shares held vs prior quarter
▲ 6.9%
Positions opened / closed
21 / 11

Top buyers and sellers, Q2 2026: 67 institutions bought and 41 sold ; the biggest buyer was Mak Capital One LLC (+474K shares) and the biggest seller SG Americas Securities, LLC (−372K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $42.5M 2.4M 17.1% ▲ 14.3%
Mak Capital One LLC $42.4M 2.4M 17.1% ▲ 24.9%
Vanguard Capital Management LLC $22M 1.2M 8.9% ▼ 0.9%
State Street Corp $14.6M 817K 5.9% ▲ 20.1%
Geode Capital Management, LLC $13.4M 750K 5.4% ▲ 6.3%
Lane Generational LLC $7.9M 445K 3.2% ▼ 8.6%
UBS Group AG $7.6M 429K 3.1% ▼ 0.9%
Millennium Management LLC $6.4M 358K 2.6% ▲ 54.2%
Brown Advisory Inc $5.8M 326K 2.3% 0.0%
Compass Financial Management LLC $5.3M 296K 2.1% —
Susquehanna International Group, LLP $4.3M 240K 1.7% ▲ 76.3%
Northern Trust Corp $4.1M 231K 1.7% ▲ 10.3%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Clearpoint Neuro, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $2.5M 9 trades by 4 insiders · 90% under pre-set plans
Net ▼ $2.5M net selling
Insider Date Trade Shares Price Value
Burnett Joseph CEO and President June 29, 2026 Sell pre-set plan 20,000 $19.38 $387,600
Burnett Joseph CEO and President June 17, 2026 Sell pre-set plan 60,000 $17.79 $1.1M
Burnett Joseph CEO and President June 17, 2026 Sell pre-set plan 1,843 $17.94 $33,063
Richards Timothy T. Director June 1, 2026 Sell 5,415 $12.17 $65,901
Klein Matthew B. Director May 21, 2026 Sell 16,000 $11.59 $185,440
Fallon Lynnette C Director May 20, 2026 Sell pre-set plan 5,091 $11.14 $56,714
Burnett Joseph CEO and President February 25, 2026 Sell pre-set plan 19,951 $15.17 $302,657
Burnett Joseph CEO and President January 26, 2026 Sell pre-set plan 2,943 $15.57 $45,823
Burnett Joseph CEO and President January 9, 2026 Sell pre-set plan 20,000 $16.12 $322,400

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 15, 2027 estimated from the company's past filing pattern, not announced

  • October 28, 2026
  • August 3, 2026
  • May 13, 2026
  • March 17, 2026
  • January 12, 2026
  • November 6, 2025

Recent SEC filings

Data status

When each part of this page on Clearpoint Neuro, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Clearpoint Neuro, Inc. in brief

What does Clearpoint Neuro, Inc. do?
Clearpoint Neuro, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Clearpoint Neuro, Inc.'s stock ticker?
Clearpoint Neuro, Inc. trades under the ticker CLPT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Clearpoint Neuro, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Clearpoint Neuro, Inc. reported revenue of $45.5M, 32.5% higher than a year earlier, according to its SEC filings.
What is Clearpoint Neuro, Inc.'s free cash flow?
Clearpoint Neuro, Inc.'s free-cash-flow margin is -105.9% of revenue over the trailing twelve months, ranking 105 of the 128 health care equipment companies we cover.
Who are Clearpoint Neuro, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Mak Capital One LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Clearpoint Neuro, Inc.'s market cap?
On November 2, 2026, Clearpoint Neuro, Inc.'s market capitalisation was about $297M and net debt of $6.3M. Market figures come from third-party market data and may be delayed.
How much debt does Clearpoint Neuro, Inc. have?
Clearpoint Neuro, Inc.'s debt-to-equity ratio is 186.5%, from its latest balance sheet (21.5% five years earlier). The financial health section below sets out its other solvency checks.
Who are Clearpoint Neuro, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Clearpoint Neuro, Inc. are Koru Medical Systems, Inc., Trisalus Life Sciences, Inc., Sanuwave Health, Inc., Myomo, Inc. and Senseonics Holdings, Inc. The side-by-side comparison below sets their revenue, margins and growth against Clearpoint Neuro, Inc.'s.
Are insiders buying or selling Clearpoint Neuro, Inc. stock?
Over the last 12 months, Clearpoint Neuro, Inc.'s directors and officers reported 0 open-market purchases and 9 sales on Form 4. The insider trading page charts every trade.
When is Clearpoint Neuro, Inc.'s next earnings date?
Around January 15, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Clearpoint Neuro, Inc. announces its own schedule.